Department of Otolaryngology Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Head and Neck Lab, 20 Staniford Street 2W, Boston, MA 02114, USA.
Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Cell Rep. 2022 Jun 14;39(11):110970. doi: 10.1016/j.celrep.2022.110970.
Analysis of The Cancer Genome Atlas and other published data of head and neck squamous cell carcinoma (HNSCC) reveals somatic alterations of the Hippo-YAP pathway in approximately 50% of HNSCC. Better strategies to target the YAP1 transcriptional complex are sought. Here, we show that FAT1, an upstream inhibitor of YAP1, is mutated either by missense or by truncating mutation in 29% of HNSCC. Comprehensive proteomic and drug-screening studies across pan-cancer models confirm that FAT1-mutant HNSCC exhibits selective and higher sensitivity to BRD4 inhibition by JQ1. Epigenomic analysis reveals an active chromatin state in FAT1-mutant HNSCC cells that is driven by the YAP/TAZ transcriptional complex through recruitment of BRD4 to deposit active histone marks, thereby maintaining an oncogenic transcriptional state. This study reveals a detailed cooperative mechanism between YAP1 and BRD4 in HNSCC and suggests a specific therapeutic opportunity for the treatment of this subset of head and neck cancer patients.
分析癌症基因组图谱和其他已发表的头颈部鳞状细胞癌(HNSCC)数据显示,Hippo-YAP 通路的体细胞改变约占 HNSCC 的 50%。人们正在寻求更好的靶向 YAP1 转录复合物的策略。在这里,我们表明,FAT1 是 YAP1 的上游抑制剂,在 29%的 HNSCC 中发生错义或截断突变。跨泛癌模型的综合蛋白质组学和药物筛选研究证实,FAT1 突变的 HNSCC 对 JQ1 抑制 BRD4 表现出选择性和更高的敏感性。表观基因组分析显示,FAT1 突变的 HNSCC 细胞中存在活跃的染色质状态,该状态通过 YAP/TAZ 转录复合物募集 BRD4 来沉积活性组蛋白标记物,从而维持致癌转录状态。这项研究揭示了 YAP1 和 BRD4 在 HNSCC 中的详细合作机制,并为治疗这部分头颈癌患者提供了特定的治疗机会。